Paloma Pharmaceuticals employs a virtual model for drug development, using a small in-house workforce to reduce cash burn and to outsource all work to specialized contract research and development groups, economizing on the expense of maintaining in-house specialized teams. This also allows for flexibility and limited down-time to train expert drug development teams.

David Sherris, Ph.D.
President and Chief Executive Officer
Dr. Sherris has over 25 years of experience in the biopharmaceutical and diagnostics world. Most recently, Dr. Sherris was the chief executive and founder of Sherris Pharma Partners, a consulting/out-sourcing company providing business development and R&D help with a niche focus in angiogenesis and vascular targeting. In addition, Dr. Sherris has worked with venture capital companies where he has both advised and raised seed money for biotech startups. Prior to his starting Sherris Pharma Partners, Dr. Sherris had been employed by pharmaceutical and biotechnology companies to manage external R&D (academic groups and contract research organizations) to augment and expand internal scientific programs. Dr. Sherris has been a frequently invited guest speaker at biopharmaceutical business and scientific conferences, a published author and holder of patents in a wide range of therapeutic areas. Dr. Sherris has held positions at Centocor, Unilever Research, Serono and OXiGENE where he was Chief Operating Officer and Vice President of Research and Development, as well as Chief Operating Officer of a joint venture between OXiGENE and Peregrine Pharmaceuticals, Arcus LLC. Dr. Sherris received his Ph.D. in Biochemistry from the University of Utah, held a postdoctoral position in immunology at the Jackson Laboratory and a faculty position in the Department of Medicine, Division of Clinical Immunology at the Mt. Sinai Medical Center, New York, NY.

Kristen Kosofsky
Director
Horizon Technology Finance LLC
Ms. Kosofsky has spent over 13 years in the venture debt market. During that period, she has focused on structuring financial transactions exclusively for biotechnology, medical device and other healthcare related companies. Prior to joining Horizon, Kristen was a Vice President at Comerica Bank from 2002-2004, where she helped to lead the Life Sciences Practice. Prior to Comerica, Kristen was one of the founding directors of GATX Ventures, where she was responsible for business development and portfolio company analysis for the Life Sciences division, which provided over $100 million in loans to Life Sciences companies. Prior to GATX, Ms. Kosofsky was employed by Transamerica Technology Finance, where she worked from 1996-2000 and was Vice President, Life Sciences. At Transamerica, Ms. Kosofsky was instrumental in the formation and growth of the $450 million Life Sciences practice. Prior to that, from 1993-1996, Ms. Kosofsky helped form the biotechnology start up division of Financing for Science International later, acquired by Finova. Ms. Kosofsky is affiliated with several industry organizations, most notably the Massachusetts Biotechnology Council's Special Finance Committee and The Biotechnology Industry Organization (BIO) where she has played an advisory role. Ms. Kosofsky holds a B.S. degree in Marketing from Central Connecticut State University (1985).

Eugene Mancino, B.A.
Director
Mancino Burfield Edgerton
Mr. Mancino has been at the forefront of life sciences executive search for more than 25 years, with clients ranging from top ten pharmaceutical corporations to the leading portfolio companies of the US and international venture capital communities. Mr. Mancino is qualified to advise both development stage and fully integrated biopharmaceutical companies with respect to operational management, strategic leadership and corporate governance. Gene has been a seed investor in, and respected advisor to, multiple life sciences companies and venture capital funds. He is currently a Business Advisor to Creative BioVentures LLC and Granite Pharmaceuticals. He is a Board Member at Juvaris BioTherapeutics located in San Francisco and a Limited Partner at Mediphase Ventures Partners and Taravel Associates LLC. He is also a seed round investor at Juvaris BioTherapeutics. He was formerly an Advisor to Aventis Capital. Mr. Mancino is frequently asked to participate on panels at various life science industry meetings, including Biotechnology Council of New Jersey, New York Biotechnology Association and Biotechnology Investor Today. Mr. Mancino is a founding partner in the life sciences search firm of Mancino Burfield Edgerton where his practice specialty is executive management including Board Directors, Chief Executive Officer, President, Chief Operating Officer, Chief Business Officer, VP's of Business Development, Sales & Marketing and Clinical/Medical Affairs. Prior to Mancino Burfield Edgerton, Mr. Mancino worked for Procter & Gamble. Mr. Mancino holds an A.B. degree in Psychology from Princeton University (1978).


The following individuals constitute the Company's Advisory Board by lending their expertise and industry experience.

Louis J. Kates, CPA
Tax and Accounting
Starr, Finer, Starr LLP
James H. Belanger, J.D.
Legal Affairs, Business Development
Burns & Levinson LLP Mr. Belanger is a partner in the Boston law firm of Burns & Levinson, LLP, where he is a member of the Corporate and Intellectual Property departments and a co-chair of the Life Sciences Group. Mr. Belanger practices corporate and technology law, and works extensively with emerging technology companies. Mr. Belanger is a member of the Massachusetts bar and the Association of University Technology Managers. He received his J.D. degree from Boston College Law School, magna cum laude, in 1972, where was the Assistant Editor-in-Chief of the Law Review and a member of the Order of the Coif, a national legal honor society. He received his A.B. from the University of Notre Dame in 1965.

Ralph DeMartino, J.D.
F. Alec Orudjev, J.D.
Corporate and Securities Counsel
Cozen O'Connor
Jay S. Duker, M.D.
Ophthalmology
Tufts New England Medical Center Dr. Duker is Professor and Chair of Ophthalmology, Tufts University School of Medicine, Director of the New England Eye Center, Vitreoretinal Diseases & Surgery Service and Director of the Pediatric Retinal Referral Center, Uveitis & Immunology Service. Dr. Duker specializes in both medical and surgical diseases of the posterior segment. His primary surgical interests include retinal detachment, proliferative vitreoretinopathy, proliferative diabetic retinopathy, retinopathy of prematurity, and posterior segment trauma with additional focus on posterior segment uveitis, AIDS-related retinitis, intraocular tumors, and retinal vascular disorders. Dr. Duker pioneered clinical use and ran clinical trials for gangcyclovir implant, one of the first implants used in ocular medicine.

Jason Slakter, M.D.
Ophthalmology
Vitreous-Retina-Macula Consultants of New York Dr. Slakter's expertise in macular disease diagnostics is extensive. He has played a leading role and is widely published in the development of digital indocyanine green angiography (ICG) for the evaluation and management of macular degeneration and chorioretinal inflammatory disease. He created and is the director of the digital Angiography Reading Center, which serves as a key resource for numerous industry sponsored studies. He has served as a Principal Investigator in the clinical trials for photodynamic therapy for the treatment of wed AMD and is currently conducting clinical studies for the treatment of central serous chorioretinopathy. Dr. Slakter is a member of numerous medical organizations including the Macular and Retina Societies, and the American Society of Retinal Specialists. He is the Editor-in-Chief of Retinal Physician, is on the editorial board of Retina and serves as a scientific review or major scientific ophthalmic journals. He is the recipient of a number of awards including the American Academy of Ophthalmology Honor Award, the Macula Society's Richard and Hinda Rosenthal Award, and the Helen Keller Manhattan League Award.

Jeffery Heier, M.D.
Ophthalmology
Ophthalmic Consultants of Boston Dr. Heier is a Vitreoretinal Specialist at Ophthalmic Consultants of Boston, Co-Director of the Vitreoretinal Fellowship at OCB/Tufts Medical School, and President of the Center for Eye Research and Education in Boston, Massachusetts. Dr. Heier is an Assistant Professor at Tufts University School of Medicine and a Clinical Instructor at Harvard University Medical School. Dr. Heier received a medical degree from Boston University School of Medicine in Massachusetts, and subsequently completed a transitional internship and ophthalmic residency at Fitzsimons Army Medical Center. Dr. Heier completed a vitreoretinal fellowship at Ophthalmic Consultants of Boston/Tufts University School of Medicine. Dr. Heier's research interests are focused on age-related macular degeneration (ARMD), diabetic retinopathy, and innovation in vitreoretinal surgical instrumentation. Dr. Heier lectures nationally and internationally regarding innovative treatments of devastating eye diseases such as macular degeneration and diabetic retinopathy.

Lee Rosen, M.D.
Oncology
Premiere Oncology Lee S. Rosen, MD President and Founder of Premier Oncology is a principal investigator for many clinical trials focusing on new cancer drug development (Phase I), particularly in the treatment of gastrointestinal malignancies. Formerly Assistant Professor in the Division of Hematology-Oncology, Department of Medicine at the University of California, Los Angeles, where he founded the Cancer Therapy Development Program, Dr. Rosen has made significant contributions to translational research with angiogenesis inhibitors, signal transduction inhibitors and new drug combinations. His work with angiogenesis inhibitors goes back to 1996 and he has since treated hundreds of patients with more than a dozen drugs in this class. In 2004, Lee S. Rosen, M.D. created Premiere Oncology to continue the research he began in 1996 as founder of the Developmental Therapeutics Program at the University of California, Los Angeles (UCLA). The program was created following completion of his fellowship and was designed to conduct early stage (Phase I and Phase II) clinical trials of novel therapeutics designed to effectively treat patients with advanced solid tumors. Dr. Rosen rapidly developed a reputation for excellence in the conduct of gastrointestinal malignancy research and early stage clinical trials for patients with solid tumors. He has led pivotal clinical trials of many products subsequently approved by the United States Food and Drug Administration (FDA) for the treatment of cancer including Camptosar (irinotecan HCL injection), Eloxatin (oxaliplatin) and Zometa (zoledronic acid for injection) and Sutent. Dr. Rosen was featured on the CBS television program 60 Minutes in 2000 for his work on angiogenesis inhibitors (a new class of drugs developed to treat cancer by inhibiting development of new blood vessels). Dr. Rosen received his Medical Degree from Baylor College of Medicine in Houston, Texas, his B.A. in English Literature from Yale University and Masters of Public Policy (M.P.P.) from Harvard University's John F. Kennedy School of Government. In addition to conducting research, Dr. Rosen speaks widely on the subject of cancer and new therapies, is an educator, and consults with research sponsors in the design of clinical trials.

Alice B. Gottlieb, M.D., Ph.D.
Dermatology
Tufts New England Medical Center Dr. Gottlieb is an internationally recognized expert and leader in the field of psoriasis and psoriatic arthritis. In March, 2006, she joined Tufts-New England Medical Center as its Chair of Dermatology and Dermatologist-in-Chief of the hospital, and as the Harvey B. Ansell Professor of Dermatology at Tufts University School of Medicine. She is the former Professor of Medicine and Founding Director of the Psoriasis Center of Excellence at UMDNJ-Robert Wood Johnson Medical School. Her research using targeted immunobiologics as pathogenic probes, provided new understanding of the pathogenesis of psoriasis and provided the foundation for biologic drug development in psoriasis and psoriatic arthritis. She has authored over 155 peer-reviewed articles. She has presented her research at more than 200 dermatology and rheumatology conferences in Europe, Asia and the United States, as well as at the FDA and the National Academy of Sciences. She is on almost every list of outstanding doctors, including Best Doctors in America and Best Doctors in Boston. She is triple boarded in dermatology, rheumatology and internal medicine, and is one of only a handful of doctors in the United States to be certified in all three of these specialties. Dr. Gottlieb has received numerous awards for mentoring and teaching including Honorary Membership in Alpha Omega Alpha in recognition of medical student teaching, a Research Mentorship award from the Internal Medicine house staff and a Mentorship Award from the American Chemical Society for mentoring minority high school students in bench and clinical research. Dr. Gottlieb is a member of the American Dermatological Association and Noah Worcester Dermatology Society amongst other professional societies.
© Paloma Pharmaceuticles, Inc. – All rights reserved